Prostin E2

Uterus evacuation, Medically induced abortion, Cervix Uteri + 4 more
Treatment
4 Active Studies for Prostin E2

What is Prostin E2

DinoprostoneThe Generic name of this drug
Treatment SummaryDinoprostone is a hormone-like substance used to soften the cervix and induce labor. It is naturally found in the body and is also available as a prescription drug in the form of a vaginal suppository. Dinoprostone helps the cervix prepare for childbirth and can also have an effect on bone resorption.
Prostin E2is the brand name
image of different drug pills on a surface
Prostin E2 Overview & Background
Brand Name
Generic Name
First FDA Approval
How many FDA approvals?
Prostin E2
Dinoprostone
1978
5

Effectiveness

How Prostin E2 Affects PatientsDinoprostone is similar to the hormone prostaglandin E2 (PGE2). It induces labor and delivery by causing the uterus to contract, and can be used to end a pregnancy. It can also cause the muscles of the digestive system to spasm, resulting in vomiting and/or diarrhea which is a common side effect of dinoprostone.
How Prostin E2 works in the bodyDinoprostone is used to induce labor by causing the uterus to contract. We don't know exactly how it works, but it is thought that it affects the calcium levels in the cell membranes and increases intracellular concentrations of a type of adenosine. Dinoprostone also causes the cervix to soften, efface, and dilate, possibly due to the enzyme collagenase which it releases.

When to interrupt dosage

The advocated measure of Prostin E2 is contingent upon the established condition, including Uterine dilation and evacuation, Cervix Uteri and Labour. The volume of dosage varies, as per the technique of delivery featured in the table underneath.
Condition
Dosage
Administration
Uterus evacuation
, 0.1 mg/mg, 10.0 mg, 0.5 mg, 20.0 mg, 0.0005 mg/mg, 0.5 mg/mL, 0.002 mg/mg, 0.001 mg/mg
Vaginal, , Insert - Vaginal, Insert, Insert, extended release - Vaginal, Gel - Endocervical, Endocervical, Tablet - Oral, Suppository, Suppository - Vaginal, Gel - Vaginal, Gel, Insert, extended release, Oral, Tablet
Medically induced abortion
, 0.1 mg/mg, 10.0 mg, 0.5 mg, 20.0 mg, 0.0005 mg/mg, 0.5 mg/mL, 0.002 mg/mg, 0.001 mg/mg
Vaginal, , Insert - Vaginal, Insert, Insert, extended release - Vaginal, Gel - Endocervical, Endocervical, Tablet - Oral, Suppository, Suppository - Vaginal, Gel - Vaginal, Gel, Insert, extended release, Oral, Tablet
Cervix Uteri
, 0.1 mg/mg, 10.0 mg, 0.5 mg, 20.0 mg, 0.0005 mg/mg, 0.5 mg/mL, 0.002 mg/mg, 0.001 mg/mg
Vaginal, , Insert - Vaginal, Insert, Insert, extended release - Vaginal, Gel - Endocervical, Endocervical, Tablet - Oral, Suppository, Suppository - Vaginal, Gel - Vaginal, Gel, Insert, extended release, Oral, Tablet
Uterine dilation and evacuation
, 0.1 mg/mg, 10.0 mg, 0.5 mg, 20.0 mg, 0.0005 mg/mg, 0.5 mg/mL, 0.002 mg/mg, 0.001 mg/mg
Vaginal, , Insert - Vaginal, Insert, Insert, extended release - Vaginal, Gel - Endocervical, Endocervical, Tablet - Oral, Suppository, Suppository - Vaginal, Gel - Vaginal, Gel, Insert, extended release, Oral, Tablet
Induction of Labour
, 0.1 mg/mg, 10.0 mg, 0.5 mg, 20.0 mg, 0.0005 mg/mg, 0.5 mg/mL, 0.002 mg/mg, 0.001 mg/mg
Vaginal, , Insert - Vaginal, Insert, Insert, extended release - Vaginal, Gel - Endocervical, Endocervical, Tablet - Oral, Suppository, Suppository - Vaginal, Gel - Vaginal, Gel, Insert, extended release, Oral, Tablet
Gestational Trophoblastic Disease
, 0.1 mg/mg, 10.0 mg, 0.5 mg, 20.0 mg, 0.0005 mg/mg, 0.5 mg/mL, 0.002 mg/mg, 0.001 mg/mg
Vaginal, , Insert - Vaginal, Insert, Insert, extended release - Vaginal, Gel - Endocervical, Endocervical, Tablet - Oral, Suppository, Suppository - Vaginal, Gel - Vaginal, Gel, Insert, extended release, Oral, Tablet
Labour
, 0.1 mg/mg, 10.0 mg, 0.5 mg, 20.0 mg, 0.0005 mg/mg, 0.5 mg/mL, 0.002 mg/mg, 0.001 mg/mg
Vaginal, , Insert - Vaginal, Insert, Insert, extended release - Vaginal, Gel - Endocervical, Endocervical, Tablet - Oral, Suppository, Suppository - Vaginal, Gel - Vaginal, Gel, Insert, extended release, Oral, Tablet

Warnings

There are 20 known major drug interactions with Prostin E2.
Common Prostin E2 Drug Interactions
Drug Name
Risk Level
Description
Carbetocin
Major
The risk or severity of adverse effects can be increased when Dinoprostone is combined with Carbetocin.
Cisplatin
Major
The serum concentration of Cisplatin can be increased when it is combined with Dinoprostone.
Clofarabine
Major
The serum concentration of Clofarabine can be increased when it is combined with Dinoprostone.
Dalfampridine
Major
The serum concentration of Dalfampridine can be increased when it is combined with Dinoprostone.
Dofetilide
Major
The serum concentration of Dofetilide can be increased when it is combined with Dinoprostone.
Prostin E2 Toxicity & Overdose RiskThe lowest toxic dose of this drug in mice has been found to be 750 mg/kg, and in rats it is 500 mg/kg.

Prostin E2 Novel Uses: Which Conditions Have a Clinical Trial Featuring Prostin E2?

Three ongoing trials are assessing the potential of Prostin E2 to provide treatment for Cervix Uteri, Medically-Induced Abortion and Uterine Dilation and Evacuation.
Condition
Clinical Trials
Trial Phases
Medically induced abortion
0 Actively Recruiting
Uterine dilation and evacuation
0 Actively Recruiting
Induction of Labour
1 Actively Recruiting
Phase 4
Gestational Trophoblastic Disease
1 Actively Recruiting
Phase 2
Labour
2 Actively Recruiting
Phase 4, Phase 3
Cervix Uteri
0 Actively Recruiting
Uterus evacuation
0 Actively Recruiting

Prostin E2 Reviews: What are patients saying about Prostin E2?

3.7Patient Review
2/5/2009
Prostin E2 for Abortion
image of drug pills surrounding a glass of water symbolizing drug consumption

Patient Q&A Section about prostin e2

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What is prostin E2 used for?

"This medication can be used to cause an abortion during the second to third trimesters of pregnancy. It can also be used to help vaginally remove any remaining material in the womb from a miscarriage or missed abortion."

Answered by AI

How does prostaglandin E2 work?

"PGE2 softens and Ripens the cervix by stimulating uterine contractions and also by directly acting on the collagenase present in the cervix. There are currently two formulations of PGE2 analog available for use in cervical ripening: Prepidil, a vaginal gel, and Cervidil, a vaginal insert."

Answered by AI

How do you use prostin E2 for abortion?

"The patient should insert a suppository containing 20 mg of dinoprostone high into the vagina, remaining in the supine position for ten minutes following insertion. additional intravaginal administration of each subsequent suppository should be at 3-to 5-hour intervals until abortion occurs."

Answered by AI

How fast does prostin work?

"If you don't start having contractions after 6 hours of taking prostin, you will be given another tablet or gel. It can take up to 24 hours for a controlled-release pessary to start working. If you don't have contractions after 24 hours, you could be given another dose."

Answered by AI

Clinical Trials for Prostin E2

Image of Sentara Norfolk General Hospital in Norfolk, United States.

Lactated Ringer's + Dextrose for Induction of Labour

18+
Female
Norfolk, VA
The goal of this clinical trial is to determine which of two types of standard intravenous (IV) fluids (a combination of 5% dextrose and Lactated Ringers solution and Lactated Ringers solution alone) has a better influence on labor when inducing labor in pregnant women. The main questions it aims to answer are: 1. Does the use of 5% dextrose and Lactated Ringers lead to a shorter labor than the use of just Lactated Ringers? 2. Does the use of 5% dextrose and Lactated Ringers increase the risk of neonatal hypoglycemia when compared to Lactated Ringers? Participants in this trial will be randomly assigned to one of two groups: a group that receives a solution of 5% dextrose and Lactated Ringers, and a group that receives Lactated Ringers alone. Researchers will compare the outcomes of the two groups to see which IV fluid is more effective.
Phase 4
Recruiting
Sentara Norfolk General Hospital
Image of Icahn School of Medicine at Mount SInai in New York, United States.

Ephedrine for Childbirth

18 - 55
Female
New York, NY
Labor analgesia is an important component of the care of laboring patients. A known side effect of combined spinal and epidural anesthesia (a type of labor analgesia) is an increased incidence of category II fetal heart rate tracing (defined below) and low blood pressure. The study team aims to study if a prophylactic dose of ephedrine will decrease the occurrence of this type of tracing after combined spinal epidural (CSE) anesthesia placement. Ephedrine is not currently routinely used as prevention for category II tracings or low blood pressure. The use of Ephedrine in this study is investigational (this is the first time that the drug has been studied for its effect on these conditions). Fetal heart rate (FHR) tracings are classified into three categories. In clinical practice, FHR tracing categories are used as a guide to obstetric management and suggest the following approach: * Category I tracing is "reactive" and reassuring → may continue labor * Category II tracing is neither category I nor category III. For obvious reasons, category II is the broadest and largest category, consisting of various FHR tracing patterns that do not fit into either category I or category III. * Category III tracing is non-reassuring → expedited vaginal or cesarean delivery recommended. A Category II tracing is not diagnostic. Most pregnancies have at least one Category II tracing. There is not always an identifiable reason for a Category II tracing. Ephedrine is a medication that causes an increase in heart rate and blood pressure while also causing some degree of relaxation of the uterus therefore improving uterine blood flow. It has been used in the obstetric population for over 50 years without issues. The dose that the research team will administer, 7.5 mg, is below the dose the research team will often administer to treat hypotension (low blood pressure).
Phase 4
Recruiting
Icahn School of Medicine at Mount SInai (+1 Sites)James Leader
Image of University of Alabama at Birmingham Cancer Center in Birmingham, United States.

Nivolumab + Ipilimumab for Rare Cancers

18+
All Sexes
Birmingham, AL
This phase II trial studies nivolumab and ipilimumab in treating patients with rare tumors. Immunotherapy with monoclonal antibodies, such as nivolumab and ipilimumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. This trial enrolls participants for the following cohorts based on condition: 1. Epithelial tumors of nasal cavity, sinuses, nasopharynx: A) Squamous cell carcinoma with variants of nasal cavity, sinuses, and nasopharynx and trachea (excluding laryngeal, nasopharyngeal cancer \[NPC\], and squamous cell carcinoma of the head and neck \[SCCHN\]) B) Adenocarcinoma and variants of nasal cavity, sinuses, and nasopharynx (closed to accrual 07/27/2018) 2. Epithelial tumors of major salivary glands (closed to accrual 03/20/2018) 3. Salivary gland type tumors of head and neck, lip, esophagus, stomach, trachea and lung, breast and other location (closed to accrual) 4. Undifferentiated carcinoma of gastrointestinal (GI) tract 5. Adenocarcinoma with variants of small intestine (closed to accrual 05/10/2018) 6. Squamous cell carcinoma with variants of GI tract (stomach small intestine, colon, rectum, pancreas) (closed to accrual 10/17/2018) 7. Fibromixoma and low grade mucinous adenocarcinoma (pseudomixoma peritonei) of the appendix and ovary (closed to accrual 03/20/2018) 8. Rare pancreatic tumors including acinar cell carcinoma, mucinous cystadenocarcinoma or serous cystadenocarcinoma. Pancreatic adenocarcinoma is not eligible (closed to accrual) 9. Intrahepatic cholangiocarcinoma (closed to accrual 03/20/2018) 10. Extrahepatic cholangiocarcinoma and bile duct tumors (closed to accrual 03/20/2018) 11. Sarcomatoid carcinoma of lung 12. Bronchoalveolar carcinoma lung. This condition is now also referred to as adenocarcinoma in situ, minimally invasive adenocarcinoma, lepidic predominant adenocarcinoma, or invasive mucinous adenocarcinoma 13. Non-epithelial tumors of the ovary: A) Germ cell tumor of ovary B) Mullerian mixed tumor and adenosarcoma (closed to accrual 03/30/2018) 14. Trophoblastic tumor: A) Choriocarcinoma (closed to accrual) 15. Transitional cell carcinoma other than that of the renal, pelvis, ureter, or bladder (closed to accrual) 16. Cell tumor of the testes and extragonadal germ tumors: A) Seminoma and testicular sex cord cancer B) Non seminomatous tumor C) Teratoma with malignant transformation (closed to accrual) 17. Epithelial tumors of penis - squamous adenocarcinoma cell carcinoma with variants of penis (closed to accrual) 18. Squamous cell carcinoma variants of the genitourinary (GU) system 19. Spindle cell carcinoma of kidney, pelvis, ureter 20. Adenocarcinoma with variants of GU system (excluding prostate cancer) (closed to accrual 07/27/2018) 21. Odontogenic malignant tumors 22. Pancreatic neuroendocrine tumor (PNET) (formerly named: Endocrine carcinoma of pancreas and digestive tract.) (closed to accrual) 23. Neuroendocrine carcinoma including carcinoid of the lung (closed to accrual 12/19/2017) 24. Pheochromocytoma, malignant (closed to accrual) 25. Paraganglioma (closed to accrual 11/29/2018) 26. Carcinomas of pituitary gland, thyroid gland parathyroid gland and adrenal cortex (closed to accrual) 27. Desmoid tumors 28. Peripheral nerve sheath tumors and NF1-related tumors (closed to accrual 09/19/2018) 29. Malignant giant cell tumors 30. Chordoma (closed to accrual 11/29/2018) 31. Adrenal cortical tumors (closed to accrual 06/27/2018) 32. Tumor of unknown primary (Cancer of Unknown Primary; CuP) (closed to accrual 12/22/2017) 33. Not Otherwise Categorized (NOC) Rare Tumors \[To obtain permission to enroll in the NOC cohort, contact: S1609SC@swog.org\] (closed to accrual 03/15/2019) 34. Adenoid cystic carcinoma (closed to accrual 02/06/2018) 35. Vulvar cancer (closed to accrual) 36. MetaPLASTIC carcinoma (of the breast) (closed to accrual) 37. Gastrointestinal stromal tumor (GIST) (closed to accrual 09/26/2018) 38. Perivascular epithelioid cell tumor (PEComa) 39. Apocrine tumors/extramammary Paget's disease (closed to accrual) 40. Peritoneal mesothelioma 41. Basal cell carcinoma (temporarily closed to accrual 04/29/2020) 42. Clear cell cervical cancer 43. Esthenioneuroblastoma (closed to accrual) 44. Endometrial carcinosarcoma (malignant mixed Mullerian tumors) (closed to accrual) 45. Clear cell endometrial cancer 46. Clear cell ovarian cancer (closed to accrual) 47. Gestational trophoblastic disease (GTD) 48. Gallbladder cancer 49. Small cell carcinoma of the ovary, hypercalcemic type 50. PD-L1 amplified tumors 51. Angiosarcoma 52. High-grade neuroendocrine carcinoma (pancreatic neuroendocrine tumor \[PNET\] should be enrolled in Cohort 22; prostatic neuroendocrine carcinomas should be enrolled into Cohort 53). Small cell lung cancer is not eligible (closed to accrual) 53. Treatment-emergent small-cell neuroendocrine prostate cancer (t-SCNC)
Phase 2
Waitlist Available
University of Alabama at Birmingham Cancer Center (+99 Sites)Sandip P Patel
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Terms of Service·Privacy Policy·Cookies·Security